130 related articles for article (PubMed ID: 21783387)
1. A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry.
Montironi R; Bartels PH; DeCensi A; Puntoni M; Hurle R; Decobelli O; Carmignani G; Mazzucchelli R; Bartels HG; Alberts DS; Maffezzini M
Urol Oncol; 2013 Jul; 31(5):557-65. PubMed ID: 21783387
[TBL] [Abstract][Full Text] [Related]
2. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
3. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
Cho YM; Takahashi S; Asamoto M; Suzuki S; Tang M; Shirai T
Prostate Cancer Prostatic Dis; 2007; 10(4):378-83. PubMed ID: 17457304
[TBL] [Abstract][Full Text] [Related]
4. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.
Kirby R; Robertson C; Turkes A; Griffiths K; Denis LJ; Boyle P; Altwein J; Schröder F
Prostate; 1999 Jul; 40(2):105-14. PubMed ID: 10386471
[TBL] [Abstract][Full Text] [Related]
5. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.
Moghetti P; Tosi F; Tosti A; Negri C; Misciali C; Perrone F; Caputo M; Muggeo M; Castello R
J Clin Endocrinol Metab; 2000 Jan; 85(1):89-94. PubMed ID: 10634370
[TBL] [Abstract][Full Text] [Related]
6. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Raghow S; Kuliyev E; Steakley M; Greenberg N; Steiner MS
Cancer Res; 2000 Aug; 60(15):4093-7. PubMed ID: 10945615
[TBL] [Abstract][Full Text] [Related]
7. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
Barqawi AB; Moul JW; Ziada A; Handel L; Crawford ED
Urology; 2003 Nov; 62(5):872-6. PubMed ID: 14624911
[TBL] [Abstract][Full Text] [Related]
8. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
Monti S; Sciarra F; Adamo MV; Toscano V; Trotta MC; Martini C; Lanzara S; Silverio FD
J Androl; 1997; 18(5):488-94. PubMed ID: 9349746
[TBL] [Abstract][Full Text] [Related]
9. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
Miller NL; Bissonette EA; Bahnson R; Wilson J; Theodorescu D
Cancer; 2003 Mar; 97(5):1203-10. PubMed ID: 12599226
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
[TBL] [Abstract][Full Text] [Related]
11. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
12. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
13. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects.
Fleshner NE; Trachtenberg J
J Urol; 1995 Nov; 154(5):1642-5; discussion 1645-6. PubMed ID: 7563310
[TBL] [Abstract][Full Text] [Related]
14. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
[TBL] [Abstract][Full Text] [Related]
15. [Finasteride and flutamide in the treatment of hirsutism].
Falsetti L; De Fusco D; Rosina B
Minerva Ginecol; 1997 Oct; 49(10):463-8. PubMed ID: 9463180
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
17. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
[TBL] [Abstract][Full Text] [Related]
18. The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.
Hernandez J; Gelfond J; Goros M; Liss MA; Liang Y; Ankerst D; Thompson IM; Leach RJ
PLoS One; 2018; 13(10):e0204823. PubMed ID: 30300367
[TBL] [Abstract][Full Text] [Related]
19. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.
Narayan P; Trachtenberg J; Lepor H; Debruyne FM; Tewari A; Stone N; Das S; Jimenez-Cruz JF; Shearer R; Klimberg I; Schellhammer PF; Costello AJ
Urology; 1996 Apr; 47(4):497-504. PubMed ID: 8638357
[TBL] [Abstract][Full Text] [Related]
20. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
